Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
AstraZeneca
NRG Oncology
Hoffmann-La Roche
Eastern Cooperative Oncology Group
AstraZeneca
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
AstraZeneca
AstraZeneca
University Health Network, Toronto
GlaxoSmithKline
AstraZeneca
Blueprint Medicines Corporation
Grupo Español de Investigación en Cáncer de Ovario
Eastern Cooperative Oncology Group
Novartis
Shanghai Henlius Biotech
Eastern Cooperative Oncology Group
Blueprint Medicines Corporation
University of Kentucky
University of Kentucky
UCB Pharma
Hoffmann-La Roche
Duke University
Eli Lilly and Company
Mereo BioPharma
University of Florida
Eli Lilly and Company
Celgene
University of Pittsburgh
Merck Sharp & Dohme LLC
AbbVie
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
Massachusetts General Hospital
SCRI Development Innovations, LLC
Oncolytics Biotech
Oncolytics Biotech
Amgen
Oncolytics Biotech
Oncolytics Biotech
Astellas Pharma Inc
Abbott
Amgen